Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks
https://finance.yahoo.com/news/efruxifermin-granted-fda-breakthrough-therapy-120000101.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.